SMYD3: A Potential Drug Target for Cancer (G64754)

Target Name: SMYD3

NCBI ID: G64754

SMYD3

SMYD3: A Potential Drug Target for Cancer

SMYD3 (Smydin-3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the Smydin family of proteins, which are known for their role in intracellular signaling. SMYD3 has been shown to play a role in a variety of physiological processes, including cell signaling, DNA replication, and stress response.

SMYD3 has also been identified as a potential drug target. Researchers have found that SMYD3 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that inhibiting SMYD3 can lead to a reduction in cancer cell proliferation and survival.

One of the reasons for SMYD3's potential as a drug target is its involvement in intracellular signaling. SMYD3 is a key regulator of the protein S100, which is involved in a variety of signaling pathways. S100 is a transcription factor that has been shown to play a role in promoting the expression of various genes, including those involved in cell growth, differentiation, and survival.

SMYD3 is also involved in the regulation of DNA replication. In cancer cells, DNA replication is a critical process that allows the cells to divide and proliferate. However, SMYD3 has been shown to play a role in regulating the DNA replication process in cancer cells. Studies have shown that inhibiting SMYD3 can lead to a reduction in cancer cell DNA replication and growth.

In addition to its involvement in intracellular signaling, SMYD3 is also involved in stress response. Stress can cause a variety of cellular changes, including increased inflammation and cellular death. SMYD3 has been shown to play a role in regulating these processes in cancer cells.

SMYD3's involvement in stress response is also relevant to its potential as a drug target. Many cancer treatments, including chemotherapy and radiation therapy, can cause stress in cancer cells. By inhibiting SMYD3, researchers hope to reduce the amount of stress caused by these treatments and improve the overall effectiveness of cancer treatments.

Another potential mechanism by which SMYD3 may be a drug target is its involvement in cell adhesion. SMYD3 is a member of the cadherin family of proteins, which are involved in cell-cell adhesion. Studies have shown that SMYD3 plays a role in regulating cell-cell adhesion in various tissues, including the brain and heart.

By inhibiting SMYD3, researchers hope to reduce cell-cell adhesion and improve the movement of cells in various tissues. This may have potential implications for the development of new treatments for various diseases, including cancer.

SMYD3 is also involved in the regulation of cell signaling pathways that are involved in cell growth and differentiation. By inhibiting SMYD3, researchers hope to reduce the amount of signal transduction that occurs within cells, which can lead to a reduction in cell growth and differentiation.

In conclusion, SMYD3 is a protein that is involved in a variety of physiological processes in the body. Its involvement in intracellular signaling, DNA replication, stress response, and cell adhesion make it a potential drug target for the development of new treatments for various diseases, including cancer. As further research continues to emerge, the potential implications of SMYD3 as a drug target will continue to grow.

Protein Name: SET And MYND Domain Containing 3

Functions: Histone methyltransferase. Specifically methylates 'Lys-4' of histone H3, inducing di- and tri-methylation, but not monomethylation (PubMed:15235609, PubMed:22419068). Also methylates 'Lys-5' of histone H4 (PubMed:22419068). Plays an important role in transcriptional activation as a member of an RNA polymerase complex (PubMed:15235609). Binds DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences (PubMed:15235609)

The "SMYD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMYD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets